^
    Back
    Association details:
    Biomarker:MAPK1 E322K
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Oncotarget
    Title:

    MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin

    Excerpt:
    We determined that MAPK1E322K HSC-6 cells were more sensitive to erlotinib than MAPK1WT Cal33 cells as assessed by senescence assay...Following 48 h treatment with erlotinib (500 nM or 5 μM) or vehicle control, HSC-6 cells had enhanced erlotinib-induced senescence compared to Cal33 cells.
    DOI:
    10.18632/oncotarget.8188
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    JAMA Oncol
    Title:

    Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma

    Excerpt:
    The HNSCC cells with MAPK1 E322K exhibited enhanced EGFR phosphorylation and erlotinib sensitivity compared with wild-type MAPK1 cells.
    DOI:
    10.1001/jamaoncol.2015.34